Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic irinotecan continuous-infusion study in metastatic colorectal cancer
2006-001045-34Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), sponsored by Azienda USL Toscana Nord Ovest. Primary endpoints: Treatment-related toxicity, Feasibility and optimal metronomic dose and 1 more. Started Mar 2006; status: active.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-001045-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001045-34.